secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001437749-24-011645
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Therapeutics SVP Julie VanOrsdel Daves resigns; Rebekah de Vitry Fries assumes clinical operations leadership
--------------------------------------------------------------------------------

- Julie VanOrsdel Daves resigns as SVP, Clinical Development Operations effective April 18, 2024 for personal reasons.
- Rebekah de Vitry Fries, current VP of Clinical Operations, will assume leadership of clinical operations.
- De Vitry Fries joined DiaMedica as a consultant on Jan 3, 2024 and became full-time employee on Feb 20, 2024.
- She previously served as Head of Clinical Operations at Epygenix Therapeutics, reporting to same CMO Lorianne Musuoka.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924011645/0001437749-24-011645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924011645/dmtp20240408_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-011645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer